JP MORGAN/CALL/ELI LILLY & CO/1270/0.01/16.01.26 Stock

Warrant

DE000JK6YC31

Real-time Bid/Ask 08:46:39 2024-05-23 EDT
0.48 EUR / 0.5 EUR +6.52% Intraday chart for JP MORGAN/CALL/ELI LILLY & CO/1270/0.01/16.01.26
Current month+43.75%
1 month+48.39%
Date Price Change
24-05-23 0.48 +4.35%
24-05-22 0.46 +17.95%
24-05-21 0.39 +5.41%
24-05-20 0.37 -2.63%
24-05-17 0.38 -7.32%

Delayed Quote Börse Stuttgart

Last update May 23, 2024 at 07:53 am

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ELI LILLY AND COMPANY
Issuer J.P. Morgan
WKN JK6YC3
ISINDE000JK6YC31
Date issued 2024-04-04
Strike 1,270 $
Maturity 2026-01-16 (603 Days)
Parity 100 : 1
Emission price 0.31
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.48
Lowest since issue 0.29
Delta0.28x
Omega 4.247
Premium64.8x
Gearing15.1x
Moneyness 0.6322
Difference Strike 467.1 $
Difference Strike %+36.78%
Spread 0.02
Spread %4.00%
Theoretical value 0.4900
Implied Volatility 36.86 %
Total Loss Probability 85.20 %
Intrinsic value 0.000000
Present value 0.4900
Break even 1,323.17 €
Theta-0.01x
Vega0.03x
Rho0.03x

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
More about the company

Ratings for Eli Lilly and Company

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Eli Lilly and Company

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
802.9 USD
Average target price
850.4 USD
Spread / Average Target
+5.92%
Consensus